Guard Therapeutics develops the investigational drug RMC-035 (ROSgard) for the treatment of acute kidney injuries.
The drug candidate RMC-035 prevents organ damage by multiple mechanisms including potent anti-oxidative effects and support of regenerative processes. The kidneys are especially sensitive to acute damage related to oxidative stress. Guard Therapeutics has chosen to focus the initial clinical development on prevention and treatment of acute kidney injury in cardiac surgery. This is considered an attractive indication based on RMC-035 mode of action, available preclinical data and developmental advantages.
Treatment with RMC-035 could save lives and prevent such chronic and grave consequences from reduced kidney function as life-supporting dialysis.
Our early clinical trials programme consists of phase 1 studies in healthy subjects and one phase Ib study in patients undergoing cardiac surgery.Read more